NanoViricides, Inc. (NYSE American: NNVC) has announced the start of patient enrollment and dosing in its Phase II clinical trial of NV-387 Oral Gummies for the treatment of Bundibugyo Ebolavirus and other Ebola viruses. The trial is taking place at an Ebola Treatment Center in the Ituri province of the Democratic Republic of Congo (DRC), with the Phase IIA portion beginning enrollment and dosing around Sept. 23. This development is important because it represents a potential new oral treatment option for Ebola, a severe and often fatal viral disease that has caused multiple outbreaks in Africa, and it underscores the progress of NanoViricides' broad-spectrum antiviral platform.
The Phase IIA portion of the study is designed to establish a safe and well-tolerated dosing protocol for NV-387, which will then be used in the Phase IIB portion to evaluate the drug's safety, tolerability, and effectiveness. The trial is registered in the Pan African Clinical Trials Registry under identification number PACTR202608748555077. For investors and industry observers, the initiation of this trial is a critical milestone for NanoViricides, as it moves its lead drug candidate into human testing for a high-priority infectious disease. The company's focus on developing a broad-spectrum antiviral that can address multiple viruses, including RSV, COVID, Influenza, and MPOX/Smallpox, could position it as a key player in the global antiviral market if successful.
NanoViricides is a clinical-stage company that creates special purpose nanomaterials for antiviral therapy. Its novel nanoviricide(TM) class of drug candidates is based on intellectual property and technology from TheraCour Pharma, Inc. The company's lead drug candidate, NV-387, is being developed as a treatment for RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox and Measles. Another advanced candidate, NV-HHV-1, is for the treatment of Shingles. The company's business model relies on licensing technology from TheraCour Pharma for specific antiviral applications, and it holds a worldwide exclusive perpetual license for several human viral diseases, including HIV/AIDS, Hepatitis B and C, Rabies, Herpes, Influenza, Dengue, Japanese Encephalitis, West Nile Virus, Ebola/Marburg, and certain Coronaviruses.
The trial's progress is closely watched by investors, as NanoViricides is listed on the NYSE American under the ticker NNVC. The latest news and updates relating to NNVC are available in the company's newsroom at https://ibn.fm/NNVC. The full press release can be viewed at https://ibn.fm/qC4Hk. For more information about NanoViricides, visit www.nanoviricides.com.
MissionIR, a specialized communications platform, has been assisting NanoViricides with syndicated content to enhance visibility within the investment community. MissionIR is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution, and a full array of tailored corporate communications solutions.
As with any drug development effort, there are substantial risks. The path to typical drug development is extremely lengthy and requires substantial capital, and there can be no assurance that any of the company's pharmaceutical candidates will show sufficient effectiveness and safety for human clinical development. Despite these risks, the initiation of the Phase II Ebola trial is a notable advancement for NanoViricides and the broader field of antiviral research, offering hope for a new oral treatment against a deadly virus.
